Articles tagged with Cancer Patients
A new study reveals that Latinos from Mexico have the lowest chance of getting colorectal cancer, while those from Central or South America are diagnosed with the disease before age 50 at a higher rate. The research aims to pave the way for personalized cancer care and reduce disparities in treatment
Thyroid cancer patients report poor quality of life after diagnosis and treatment compared to other patients with more lethal cancers. Researchers found that thyroid cancer survivors reported an average quality of life score of 5.56 out of 10, which is worse than other cancer types.
A single dose of psilocybin significantly decreases anxiety and depression in cancer patients, with positive effects lasting up to 6 months. The study suggests that psilocybin may be a sufficient treatment for mood disturbances in cancer patients.
A study identified significant differences in cancer genome sequencing procedures and quality among research institutions, leading to inconsistencies in detected mutations. A reference mutation dataset has been established to improve procedures for identifying true somatic mutations in cancer genomes.
Recent studies present new data on the myRisk Hereditary Cancer test, highlighting its ability to identify patients with deleterious mutations who may have been missed by traditional genetic testing. The test demonstrated a significant increase in identifying BRCA-related mutations among those tested without BRCA1/2 results.
A gold standard data record has been established to improve cancer genome analysis and detect somatic mutations reliably. The record, obtained from interlaboratory testing, provides a basis for laboratories to evaluate their bioinformatic methods and thresholds for detecting specific mutations.
Research from the University of Pennsylvania School of Medicine found that pre- and post-test counseling for genetic mutations increases knowledge and decreases anxiety in BRCA-negative patients. After testing, most women reported declines in general anxiety and improvements in genetic knowledge.
A Singapore-led team, with support from the Swiss Rising Tide Foundation, is conducting a Phase III clinical trial to evaluate Aspirin as secondary prevention therapy for patients with established colorectal cancer. The study aims to determine the effectiveness of Aspirin in reducing cancer recurrence and mortality.
A phase I/II clinical trial found that acalabrutinib promotes high response rates and durable results in patients with relapsed chronic lymphocytic leukemia while producing minimal side effects. The drug's selective blockade of the BTK pathway may offer improved tolerability compared to other treatments.
Researchers developed a new index identifying concurrent but unrelated diseases among AYA cancer patients, highlighting prevalence of mental illness, obesity, and cardiovascular conditions. The AYA HOPE Comorbidity Index can predict service needs and improve treatment outcomes for young cancer patients.
A study of 87 CLL patients found 12 genetic mutations that can be targeted by therapies already available for other cancers, including PARP and BRAF inhibitors. These mutations were detected through next-generation sequencing and may offer new treatment options for patients who fail current therapies.
Yale researchers developed a high-dose flu vaccine strategy that lowered infection rates by 64% among patients with immune system cancers. The novel dosing schedule improved protection against all flu strains in 66% of patients, offering promising results for cancer patient populations.
Researchers report improvements in four children treated with gene therapy for Wiskott-Aldrich syndrome, including reduced bleeding events and improved immunologic symptoms. The treatment's long-term safety and efficacy remain to be assessed as the children are monitored for 15 years.
Scientists create virtual tumors to test drug treatments, achieving an 85-86% correlation with lab results. The goal is a patient-specific workflow for early diagnosis and effective treatment identification.
A new study in mice successfully preserved fertility using ovarian follicles, producing live births and addressing concerns about reintroducing cancer cells. The technique could be beneficial for women with cancer who cannot afford to delay treatment.
The EurocanPlatform project has led to the establishment of Cancer Core Europe, a long-term initiative between six leading cancer centers aiming to create a single virtual 'e-hospital' with powerful translational platforms. This will provide robust computational biology pipelines and standardized imaging for personalized cancer medicine.
Researchers found that different regions of a single tumor shared varying levels of genetic mutations, ranging from 67% to 93%. This variation could make it harder for targeted therapies to work effectively. The study's findings have significant implications for treatment recommendations and patient care.
A feasibility study found that women with breast cancer experienced improved feelings of positivity, control, and meaning after tending small indoor 'garden bowls'. The benefits were attributed to the process of nurturing and reflecting on the garden, suggesting a simple ecotherapy-based intervention can have significant impacts.
Researchers at Kyoto University have discovered that an antibody called nivolumab may help patients with platinum-resistant ovarian cancer heal themselves by targeting the PD-1 signal. A phase II clinical trial found that most patients treated with nivolumab experienced a median overall survival of 20 months.
A study published in Radiology found that MRI-detected multicentric cancers are larger and potentially more aggressive than index cancers detected by mammography, necessitating treatment changes. In 25% of cases, these multicentric cancers were over 1 centimeter in size.
A recent EORTC study identified key health-related quality of life (HRQOL) components to prioritize in caring for older cancer patients. The study found that HRQOL improves with age for social functioning and financial problems, while physical functioning and constipation worsen.
A preclinical study finds that AR-42, an HDAC inhibitor, preserves muscle health and function while stopping life-threatening muscle wasting associated with advanced cancers. The experimental agent was shown to have a strong protective effect against tumor-associated muscle wasting in two preclinical models.
The Translational Oncology Initiative aims to connect scientists and clinicians to develop life-saving therapies for cancer patients. The 'Trojan Horse' therapy uses a virus hidden in immune cells to destroy cancer cells from within.
A new template published by ASTRO streamlines post-treatment care for cancer survivors, facilitating consistency and reducing provider burden. The template includes elements required by CoC accreditation requirements, coordinating care among primary care providers, radiation specialists, and patients.
Researchers found that combinations of non-toxic chemicals, many derived from plants and foods, may stop untreatable cancers and prevent disease relapses. The task force identified 74 molecular targets with potential anti-cancer effects, paving the way for low-cost therapies.
Researchers at the University of Montreal Hospital Research Centre have developed a new injectable biogel that can deliver anti-cancer agents directly into cancerous tumours. The biogel is effective in killing cancer cells and has shown promising results in laboratory tests, including the destruction of melanoma and kidney cancer cells.
Researchers analyzed genomic data from 1,120 pediatric cancer patients and found that 8.5% had pathogenic germline mutations in cancer predisposition genes. This study suggests that comprehensive genomic screening may be necessary for all pediatric cancer patients, not just those with a family history of cancer.
A global task force of 180 scientists has identified high-priority molecular targets for improved patient outcomes in most cancers. The team recommends low-toxicity approaches using non-toxic chemicals, including those found in plants and foods, to reach a broad-spectrum of priority targets.
A novel immunotherapeutic approach, personalized peptide vaccination, showed significant improvement in overall survival for patients with advanced bladder cancer. The study found a median overall survival of almost twice as long as that for patients without the treatment, at 7.9 months versus 4.1 months.
A recent study found that 8.5% of children with cancer have genetic mutations increasing their risk, highlighting the need for improved counseling and family testing. The study's author, Dr. John M. Maris, emphasizes the importance of understanding how other genes interact with these mutations to cause cancer in children.
A broad-spectrum approach to cancer treatment and prevention is being developed by researchers, focusing on low-toxicity agents from plants and foods that target multiple pathways involved in cancer development. The approach aims to improve upon current targeted therapies and reduce costs associated with toxicity and treatment duration.
A meta-analysis of traditional Chinese medicine and nonpharmacological interventions found that they alleviate symptoms such as depression, fatigue, and pain in Chinese cancer patients. These interventions include acupuncture, therapeutic massage, stress management, cognitive behavioral therapy, and physical training.
Men with prostate cancer who undergo radiation therapy can benefit from yoga, which stabilizes fatigue, sexual health, and urinary incontinence. Yoga also improves general quality of life by reducing cancer-related fatigue and strengthening pelvic floor muscles.
African-American women with a healthier diet, based on the Alternate Healthy Eating Index-2010 (AHEI-2010), were 34% less likely to be diagnosed with ovarian cancer. The study found that higher vegetable intake and lower intake of empty calories contributed to the reduced risk.
Early-stage non-small cell lung cancer patients receive varying levels of curative-intent surgery across US states, with disparities seen by race and socioeconomic factors. The study found that Massachusetts had the highest rates of curative surgery, while Wyoming had the lowest rate at 25%.
A new study analyzed 527 patients who underwent spinal fusion surgery using recombinant human bone morphogenetic protein (rhBMP) and found high rates of successful fusion and low rates of complications. The study found no significantly increased risk of cancer, contradicting previous concerns.
A study found that kidney failure patients on dialysis were at high risk of kidney and thyroid cancers, while those post-transplant were at higher risk of non-Hodgkin lymphoma and melanoma. The findings highlight the importance of cancer screening and prevention in these patients.
Dr. Electra Paskett receives AACR Distinguished Lecture on Cancer Health Disparities for her decades-long contributions to reducing cancer health disparities among underserved populations. Her work has led to critically important improvements in cancer screening and care, earning her international recognition as a leader in the field.
A phase I clinical trial found that pevonedistat, a small-molecule inhibitor of the NEDD8-activating enzyme, was safe and tolerable in heavily pretreated patients with relapsed/refractory lymphoma. The therapeutic showed modest activity in these patients, with three achieving partial responses and 30 experiencing stable disease.
Researchers from the University of Leicester have announced a breakthrough advance in treating chronic lymphocytic leukemia and non-Hodgkin lymphoma patients who are refractory or resistant to current chemotherapies. The new drug, ONO/GS-4059, targets BTK protein and has shown promising results with minimal toxicities.
A new blood test can detect when breast cancers become resistant to standard hormone treatment, allowing for early identification and alternative treatment options. Researchers developed the test to identify ESR1 mutations, which convey resistance to hormone treatment.
Researchers recommend hospitals create bereavement programs to support families through grief, preventing physical and mental health problems. The Dana-Farber Cancer Institute's program has shown positive effects, including a reduction in dysfunctional bereavement and its associated health issues.
A new study links high-temperature cooking of red and white meat to increased risk of kidney cancer, citing the presence of carcinogenic compounds such as PhIP and MeIQx. The study suggests that reducing meat consumption, especially when cooked at high temperatures, may help mitigate this risk.
Researchers discovered brain cancer cells form a complex network to resist treatment and invade healthy brain tissue. The tumor cells use this network to communicate and repair damage, making it resistant to radiation therapy.
A genetic biomarker called loss of heterozygosity (LOH) predicts which patients with premalignant mouth lesions are at highest risk of developing oral cancer. The study found that LOH-positive patients had a three-year cancer-free survival rate of 74% compared to 87% for LOH-negative patients.
Researchers at Ohio State University discovered a key molecule that enables cancer cells to produce lipids, leading to rapid tumor growth. Blocking this molecule may slow tumor growth and provide new therapeutic strategies for glioblastoma and other cancers.
A new clinical trial is proposed to investigate the best ways for identifying and treating advanced breast cancer patients who can survive for long periods without their disease progressing. The guidelines emphasize the importance of harnessing technology to improve cancer treatment, particularly for patients in remote areas.
A team of top researchers, led by TGen's Dr. Daniel D. Von Hoff, aims to develop therapies that greatly improve patient survival. They will focus on reprogramming the 'super enhancers' in cancer cells to stop tumor growth and offer novel treatments for patients with pancreatic cancer.
A team of top researchers will focus on reprogramming pancreatic tumor biology using cutting-edge technology and developing new SE-targeted drugs. The goal is to dial up sensitivity to chemotherapy and push tumors into lasting remission.
A genetic biomarker called loss of heterozygosity (LOH) predicts which patients with premalignant mouth lesions are at highest risk of developing oral cancer. The study found that LOH-positive patients had a lower three-year cancer-free survival rate, but no benefit from erlotinib treatment.
A phase 2 study found that 42% of older patients with acute myeloid leukemia (AML) can remain cancer-free after reduced-intensity stem cell transplantation, challenging traditional age-based exclusion criteria. This approach may offer improved outcomes for AML patients over 60 with otherwise well-tolerated treatments.
Researchers found that analyzing circulating tumor DNA can track a patient's cancer evolution and identify the best treatments. The liquid biopsy test is less invasive and less costly than conventional tissue biopsies, providing up-to-date information on how a patient's cancer is changing.
Research found that average survival was less than six months, with only 36% surviving beyond one year. Patients diagnosed through emergency routes tend to have more advanced cancers, contributing to a poorer prognosis. The study highlights the importance of early diagnosis in improving cancer survival rates.
Ahnna Parkhurst, a 15-year-old racing prodigy, is raising awareness and research dollars for the Translational Genomics Research Institute (TGen) through Laurie's Fund. Her efforts have raised over $111,000 to support cancer research and treatments.
Despite progress, cancer care in Latin America remains hindered by significant gaps in public expenditure on health and cancer care. The region still faces major challenges, including limited palliative care services, inadequate training in pain management, and underutilization of new technologies.
The FDA has approved talimogene laherparepvec (T-VEC), a herpes cold sore virus designed to kill tumor cells, as a treatment for late-stage melanoma. The therapy showed a durable response in 16% of patients, with some experiencing no signs of cancer after treatment.
A new study of over 25,000 men has identified four new genetic variants associated with an increased risk of testicular cancer. Testing for these variants combined with existing knowledge has revealed that men in the top one per cent of genetic risk have a ten-fold elevated risk of developing testicular cancer.
A retrospective survival analysis of 229 patients with late-stage cancer found that those who received methylnaltrexone lived twice as long and had fewer tumor progression reports compared to placebo groups. The study suggests methylnaltrexone may play a role in cancer therapy, but the exact mechanism is unclear.
A new collaborative research project, ISIBELa, is investigating the risk of secondary cancer in later life following successful childhood cancer therapy. Researchers will analyze cases, examine patient differences, and use advanced laboratory techniques to identify genetic and epigenetic causes.
The USPSTF recommends screening overweight and obese adults between 40-70 for abnormal blood sugar, referring those with high blood sugar to intensive behavioral counseling. Abnormal blood sugar levels increase risk of developing type 2 diabetes, which has risen in prevalence over the past 15 years.